Quanex Building Products NX Options canceled (in dollars per share)

Options canceled (in dollars per share) at other companies

Ondas, Inc. ONDS

$5.42+274%

XylemXYL

$127.87+13.3%

Oruka Therapeutics, Inc.ORKA

$15.04—

Avanos MedicalAVNS

$31.83-14.8%

Playtika Holding Corp.PLTK

$16.65-12.0%

Bicara TherapeuticsBCAX

$0.00—

Other financials

Income statement

See full

Revenue$462.4M+2.2%

Gross profit$117.8M-10.3%

Operating income$18.7M-54.3%

Net income$3.4M-83.7%

EPS (diluted)$0.07-84.1%

Balance sheet

See full

Cash & equivalents$66.0M+1.8%

Total debt$915.9M-9.7%

Total equity$727.4M-27.4%

Total assets$2.0B-13.7%

Cash flow

See full

Operating cash flow-$20.2M-61.5%

CapEx$11.0M-26.1%

Free cash flow-$31.5M-30.5%

Valuation

See full

Market cap$818.44M-2.3%

Enterprise value$1.67B-6.6%

P/S0.4×-0.1×

Profitability

See full

Gross margin26.5%+1.2pp

Operating margin-12.7%-21.2pp

Net margin-14.9%—

FCF margin5.1%—

Returns & leverage

See full

Return on equity-32%—

Debt / equity1.3×+0.2×

Current ratio2.3×-0.1×

Where this comes from

Reported directly by Quanex Building Products in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.

The official record: Quanex Building Products’s 10-Q, filed March 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Quanex Building Products's options canceled (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Quanex Building Products's options canceled (in dollars per share)?: Quanex Building Products (NX) reported options canceled (in dollars per share) of $19.30 in Q4 2025.